In Stock
Sacubitril + Valsartan Tablets
Sacubitril + Valsartan Tablets 24mg + 26mg | Cardiac / Hypertension
- Product Form: Raw Powder / API
- Not for direct consumer use
- For qualified buyers, formulation, compounding, R&D, and regulated business use only
- COA/MSDS available upon request
- Final sale depends on buyer country import regulations
Disclaimer: Products listed on this website are intended for qualified business buyers, research, formulation, compounding, or regulated pharmaceutical use only. Products are not intended for direct consumer use. Import permission, registration, customs clearance, and local regulatory compliance are the responsibility of the buyer in their respective country.
Description
This document provides clear, patient-focused product information for the generic combination of Sacubitril 24 mg + Valsartan 26 mg, presented as a generic product information sheet. Sections include Product Introduction, Uses, Benefits, Side Effects, Safety Advice, How It Works, How to Use, Quick Tips, and Drug Interactions. This is intended for informational purposes and does not replace professional medical advice. Consult your doctor or pharmacist for personalised guidance.
Product Introduction
Sacubitril + Valsartan is a fixed-dose combination medicine used to treat certain types of heart failure. It pairs two active ingredients with complementary actions to reduce strain on the heart, improve heart function, and lower the risk of hospitalisation for heart failure. The combination is commonly prescribed for patients with chronic heart failure with reduced ejection fraction (HFrEF) as part of a broader heart-failure treatment plan. The 24 mg/26 mg dose is typically a starting or titration dose; doctors adjust dosing based on response and tolerability.
Uses
-
Treatment of chronic heart failure with reduced ejection fraction (HFrEF) to reduce the risk of cardiovascular death and heart-failure related hospitalisation.
-
Used as part of a long-term treatment plan together with lifestyle measures and other therapies as advised by a physician.
-
May be used to replace or follow ACE inhibitor or ARB therapy in eligible patients under medical supervision.
Benefits
-
Reduces risk of heart-failure hospitalisation and cardiovascular death compared with standard therapy: clinical trials have shown that this combination can improve outcomes in appropriate patients.
-
Improves symptoms: may reduce breathlessness, fluid retention, and fatigue associated with heart failure over time.
-
Improves cardiac function: by reducing the workload on the heart and decreasing harmful neurohormonal activation, it can improve how the heart pumps.
-
Convenience: fixed-dose combination reduces pill burden compared with taking components separately, which can improve adherence.
How It Works
The combination includes two complementary agents:
-
Sacubitril: a neprilysin inhibitor. Neprilysin is an enzyme that degrades beneficial peptides such as natriuretic peptides, bradykinin, and adrenomedullin. Inhibiting neprilysin increases levels of these peptides, which promote vasodilation (widening of blood vessels), reduce sodium retention, and counter harmful neurohormonal systems active in heart failure.
-
Valsartan: an angiotensin II receptor blocker (ARB). It blocks the angiotensin II type 1 (AT1) receptor, reducing the effects of angiotensin II — namely vasoconstriction, aldosterone release, sodium and water retention, and sympathetic activation. This lowers blood pressure and decreases cardiac workload.
-
Together: sacubitril augments beneficial vasodilatory peptides while valsartan blocks harmful angiotensin II effects. The dual mechanism reduces cardiac stress and improves haemodynamics more than either mechanism alone in appropriate patients.
Side Effects
Common and important side effects to be aware of:
| Frequency | Side effects | Notes |
|---|---|---|
| Common (≥1%) | Dizziness | Often related to lowered blood pressure; more likely when starting or increasing dose. |
| Common (≥1%) | Hypotension (low blood pressure) | May cause lightheadedness; risk increases with diuretics, dehydration, or salt restriction. |
| Common (≥1%) | Hyperkalaemia (high potassium) | Particularly in patients with kidney impairment or on potassium supplements/ potassium-sparing drugs. |
| Common (≥1%) | Cough (less frequent than with ACE inhibitors) | Cough can occur but is typically less than with ACE inhibitors. |
| Less common | Renal function decline | Serum creatinine may increase; monitoring recommended. |
| Rare | Angioedema | Swelling of face, lips, tongue, or throat is serious—seek immediate medical attention. Risk may be higher in certain populations. |
This list does not include all possible side effects. If you experience severe symptoms such as trouble breathing, swallowing, severe rash, fainting, or marked swelling, seek emergency care. Inform your prescriber about any persistent or bothersome side effects.
Safety Advice
-
Do not use with an ACE inhibitor: Combining sacubitril with an ACE inhibitor significantly increases the risk of angioedema. If switching from an ACE inhibitor, a washout period (usually 36 hours) is required before starting sacubitril/valsartan.
-
Kidney function and potassium monitoring: Check renal function (serum creatinine) and serum potassium before starting, within 1–2 weeks of initiation or dose changes, and periodically thereafter.
-
Use caution in low blood pressure: Patients with symptomatic hypotension, volume depletion, or receiving high-dose diuretics may need dose adjustments or correction of volume status before starting.
-
Pregnancy and breastfeeding: Not recommended. Angiotensin receptor blockers like valsartan can cause fetal harm if used during pregnancy. Women of childbearing potential should use effective contraception and notify their doctor if pregnant or planning pregnancy.
-
Allergy/angioedema history: Inform your prescriber if you have a prior history of angioedema with ACE inhibitors, ARBs, or neprilysin inhibitors.
-
Liver impairment: Use caution and consult a doctor if you have significant liver disease; dosing and suitability depend on severity.
-
Inform about other medicines: Provide a full list of medications, supplements (especially potassium supplements), and herbal products to your healthcare provider to check for interactions.
How to Use
-
Follow the prescription: Take exactly as prescribed by your doctor. The 24 mg/26 mg formulation may be an initial or titration dose; do not change dose without medical advice.
-
Administration: Usually taken orally, with or without food, at the same time each day to maintain consistent blood levels.
-
Missed dose: If you miss a dose, take it as soon as you remember on the same day. Do not double doses to make up for a missed dose. If you are unsure, contact your pharmacist or doctor.
-
Dose titration: Doctors commonly titrate dose upward over weeks based on blood pressure, kidney function, and tolerability until reaching an effective maintenance dose.
-
Monitoring: Regular follow-up visits are important for blood pressure, kidney function, and potassium monitoring, especially during initiation and dose changes.
Quick Tips (Patient-friendly reminders)
-
Take at the same time each day to help remember.
-
Drink adequate fluids unless your doctor advises fluid restriction; however, avoid dehydration which can worsen low blood pressure and kidney function.
-
Avoid starting new potassium supplements or potassium-sparing diuretics without checking with your doctor.
-
Check blood pressure regularly at home, especially during the first weeks after starting or after dose changes.
-
If you feel dizzy or faint, sit or lie down and contact your doctor—this may be a sign of low blood pressure.
-
Carry a list of all your medicines because several common drugs (NSAIDs, some diuretics, potassium supplements) may interact.
-
Do not take an ACE inhibitor within 36 hours before starting this medicine; tell any prescriber you have been prescribed sacubitril/valsartan.
Drug Interactions
Important interactions to consider before starting or while taking sacubitril/valsartan:
| Drug or drug class | Interaction effect | Advice |
|---|---|---|
| ACE inhibitors | Increased risk of angioedema and other adverse effects | Do not co-administer. Allow a washout period (commonly 36 hours) after stopping an ACE inhibitor before starting sacubitril/valsartan. |
| Potassium-sparing diuretics, potassium supplements, potassium-containing salt substitutes | Increased risk of hyperkalaemia (high potassium) | Avoid or monitor potassium frequently; adjust doses as needed. |
| NSAIDs (including ibuprofen, naproxen) | May impair kidney function and reduce antihypertensive effect; combined use increases risk of renal impairment | Use cautiously, monitor kidney function; avoid long-term NSAID use if possible. |
| Lithium | Potential for increased lithium levels and lithium toxicity | Avoid combination if possible; if co-administration is necessary, monitor lithium levels closely. |
| Other ARBs or aliskiren (direct renin inhibitor) | Additive effects on blood pressure and potassium; aliskiren plus ARB in diabetes/renal impairment is contraindicated | Do not use sacubitril/valsartan with another ARB or with aliskiren in patients with diabetes or renal impairment. |
| Diuretics (loop or thiazide) | May increase risk of low blood pressure or kidney function changes when combined | Monitor blood pressure and renal function; dose adjustments may be needed. |
| Drugs affecting renin-angiotensin-aldosterone system (RAAS) | Additive effects on blood pressure, kidneys, and potassium | Exercise caution, monitor labs and blood pressure frequently. |
This table highlights key interactions but is not exhaustive. Always provide your healthcare provider with a complete list of prescription and non-prescription medications, vitamins, and herbal products. A pharmacist can review for interactions when you pick up your prescription.
When to Contact a Healthcare Provider
-
Symptoms of angioedema: swelling of face, lips, tongue, throat; difficulty breathing or swallowing — seek emergency care immediately.
-
Severe dizziness, fainting, or persistently low blood pressure readings.
-
Marked decrease in urine output or signs of kidney problems (sudden fatigue, swelling, unexplained weight gain).
-
Severe or persistent side effects such as severe rash, muscle weakness, irregular heartbeat, or severe gastrointestinal symptoms.
Final Notes
This informational document summarises commonly accepted clinical information about the sacubitril/valsartan combination. Individual recommendations may vary depending on a patient’s medical history, other medications, laboratory results, and local regulatory guidance. Always follow the prescribing physician’s instructions and consult a healthcare professional before making any changes to your medication regimen. If you would like, I can also produce a printable one-page patient leaflet or include dosing titration examples for typical practice scenarios (if you confirm patient population and previous medicines).
| Product Name | Sacubitril + Valsartan Tablets |
| Category | All Medicines, Cardiac / Hypertension |
| Form | Raw Powder |
| Grade | As per available specification |
| Documents | COA, MSDS, Invoice, Packing List |
| Packing | As per order quantity |
| MOQ | On request |
| Shipment | Air cargo / courier / buyer-approved route |
| Use | B2B, formulation, compounding, research & qualified buyer supply |
| Disclaimer | Subject to buyer country regulations |
Additional information
| Strength | 24mg + 26mg |
|---|
Customer Reviews
Only logged in customers who have purchased this product may leave a review.
